MASAC Issues Safety Information Update on Emicizumab (HEMLIBRA)

Medical News
The National Hemophilia Foundation’s Medical and Scientific Advisory Council (MASAC) has released a safety information update about Emicizumab (Hemlibra), a new subcutaneous treatment for hemophilia A patients with inhibitors. This update has been released following the first report of an anti-drug antibody to Emicizumab. MASAC’s update issues recommendations for providers and patients in case of observed loss of efficacy, updates about recent safety communications, and reviews monitoring systems and processes for investigational medicines including post-authorization. Read the MASAC update here:
Read Genentech’s statement about the development of an anti-drug antibody in a patient enrolled in the Phase III HAVEN 2 trial:
HFA does not make medical recommendations and encourages hemophilia patients to engage in an active role in your own health care and to speak with your doctors regularly on questions of treatment therapy.